TScan Therapeutics Ownership 2024 | Who Owns TScan Therapeutics Now?


OverviewForecastRevenueFinancialsChart

Institutional Ownership

52.04%

Insider Ownership

0.86%

Retail Ownership

47.09%

Institutional Holders

65.00

TScan Therapeutics Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
LYNX1 CAPITAL MANAGEMENT LP7.96%10.75%5,224,600--41,483,324Mar 31, 2024
ECOR1 CAPITAL, LLC7.62%1.00%5,000,000--39,700,000Mar 31, 2024
ADAGE CAPITAL PARTNERS GP, L.L.C.5.95%0.06%3,900,000--30,966,000Mar 31, 2024
BVF INC/IL4.56%0.65%2,989,474--23,736,424Mar 31, 2024
BAKER BROS. ADVISORS LP4.25%0.28%2,784,792--22,111,248Mar 31, 2024
PROPEL BIO MANAGEMENT, LLC3.18%9.65%2,087,139--16,571,884Mar 31, 2024
VANGUARD GROUP INC2.76%0.00%1,808,15220,0001.12%14,356,727Mar 31, 2024
BLACKROCK INC.2.59%0.00%1,699,21327,4861.64%13,491,751Mar 31, 2024
DEER MANAGEMENT CO. LLC1.90%1.79%1,245,504-1-0.00%9,889,302Mar 31, 2024
ALPHABET INC.1.64%0.34%1,077,080--8,552,015Mar 31, 2024
SIMPLIFY ASSET MANAGEMENT INC.1.60%0.49%1,046,916--8,312,513Mar 31, 2024
DC FUNDS, LP0.96%48.34%630,000--5,002,200Mar 31, 2024
INVESCO LTD.0.74%0.00%488,415488,415100.00%3,878,015Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC0.63%0.00%413,77922,1335.65%3,286,207Mar 31, 2024
MILLENNIUM MANAGEMENT LLC0.60%0.00%392,115293,033295.75%3,113,393Mar 31, 2024
LAURION CAPITAL MANAGEMENT LP0.55%0.02%362,484302,084500.14%2,878,123Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.45%0.00%297,902297,902100.00%2,365,342Mar 31, 2024
GOLDMAN SACHS GROUP INC0.40%0.00%260,148229,863759.00%2,065,575Mar 31, 2024
MORGAN STANLEY0.34%0.00%223,894-10,809-4.61%1,777,719Mar 31, 2024
TOCQUEVILLE ASSET MANAGEMENT L.P.0.32%0.03%212,200212,200100.00%1,684,868Mar 31, 2024

TScan Therapeutics's largest institutional shareholder is LYNX1 CAPITAL MANAGEMENT LP, holding 7.96% of the company's total share outstanding, currently valued at $41.48M. The top 10 institutional shareholders own together 42.40% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
DC FUNDS, LP0.96%48.34%630,000--5,002,200Mar 31, 2024
LYNX1 CAPITAL MANAGEMENT LP7.96%10.75%5,224,600--41,483,324Mar 31, 2024
PROPEL BIO MANAGEMENT, LLC3.18%9.65%2,087,139--16,571,884Mar 31, 2024
DEER MANAGEMENT CO. LLC1.90%1.79%1,245,504-1-0.00%9,889,302Mar 31, 2024
ECOR1 CAPITAL, LLC7.62%1.00%5,000,000--39,700,000Mar 31, 2024
BVF INC/IL4.56%0.65%2,989,474--23,736,424Mar 31, 2024
SIMPLIFY ASSET MANAGEMENT INC.1.60%0.49%1,046,916--8,312,513Mar 31, 2024
CANNON GLOBAL INVESTMENT MANAGEMENT, LLC0.03%0.37%17,50017,500100.00%138,950Mar 31, 2024
ALPHABET INC.1.64%0.34%1,077,080--8,552,015Mar 31, 2024
BAKER BROS. ADVISORS LP4.25%0.28%2,784,792--22,111,248Mar 31, 2024
DC INVESTMENTS MANAGEMENT, LLC0.05%0.23%35,563--282,370Mar 31, 2024
PRIVIUM FUND MANAGEMENT (UK) LTD0.02%0.06%15,825--126,758Mar 31, 2024
ADAGE CAPITAL PARTNERS GP, L.L.C.5.95%0.06%3,900,000--30,966,000Mar 31, 2024
CTC ALTERNATIVE STRATEGIES, LTD.0.02%0.05%11,00011,000100.00%87,340Mar 31, 2024
POINT72 ASIA (SINGAPORE) PTE. LTD.0.03%0.04%19,73619,736100.00%156,704Mar 31, 2024
MARATHON TRADING INVESTMENT MANAGEMENT LLC0.08%0.03%51,00051,000100.00%404,940Mar 31, 2024
TOCQUEVILLE ASSET MANAGEMENT L.P.0.32%0.03%212,200212,200100.00%1,684,868Mar 31, 2024
ARIES WEALTH MANAGEMENT0.02%0.03%10,000--79,400Mar 31, 2024
LAURION CAPITAL MANAGEMENT LP0.55%0.02%362,484302,084500.14%2,878,123Mar 31, 2024
PALE FIRE CAPITAL SE0.03%0.02%21,573--171,290Mar 31, 2024

The largest TScan Therapeutics shareholder by % of total assets is DC FUNDS, LP. The company owns 630.00K shares of TScan Therapeutics (TCRX), representing 48.34% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
INVESCO LTD.0.74%0.00%488,415488,415100.00%3,878,015Mar 31, 2024
LAURION CAPITAL MANAGEMENT LP0.55%0.02%362,484302,084500.14%2,878,123Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.45%0.00%297,902297,902100.00%2,365,342Mar 31, 2024
MILLENNIUM MANAGEMENT LLC0.60%0.00%392,115293,033295.75%3,113,393Mar 31, 2024
GOLDMAN SACHS GROUP INC0.40%0.00%260,148229,863759.00%2,065,575Mar 31, 2024
TOCQUEVILLE ASSET MANAGEMENT L.P.0.32%0.03%212,200212,200100.00%1,684,868Mar 31, 2024
MARSHALL WACE, LLP0.29%0.00%191,17180,62072.93%1,517,898Mar 31, 2024
STATE STREET CORP0.21%-135,00073,900120.95%1,071,900Mar 31, 2024
JANE STREET GROUP, LLC0.23%0.00%153,13369,51183.13%1,215,876Mar 31, 2024
QUBE RESEARCH & TECHNOLOGIES LTD0.22%0.00%143,53663,54779.44%1,139,676Mar 31, 2024
MARATHON TRADING INVESTMENT MANAGEMENT LLC0.08%0.03%51,00051,000100.00%404,940Mar 31, 2024
CITIGROUP INC0.18%0.00%116,92143,75859.81%928,353Mar 31, 2024
TWO SIGMA INVESTMENTS, LP0.06%0.00%37,74737,747100.00%299,711Mar 31, 2024
HRT FINANCIAL LP0.05%0.00%34,78934,789100.00%276,000Mar 31, 2024
WALLEYE CAPITAL LLC0.08%0.00%52,47834,701195.20%416,675Mar 31, 2024
BREVAN HOWARD CAPITAL MANAGEMENT LP0.05%0.00%34,57834,578100.00%274,549Mar 31, 2024
JPMORGAN CHASE & CO0.10%-67,01333,783101.66%532,083Mar 31, 2024
BLACKROCK INC.2.59%0.00%1,699,21327,4861.64%13,491,751Mar 31, 2024
MAN GROUP PLC0.12%0.00%77,33926,92953.42%614,072Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.07%0.00%47,00025,300116.59%373,000Mar 31, 2024

As of Mar 31 2024, TScan Therapeutics's largest institutional buyer is INVESCO LTD.. The company purchased 488.42K stocks of TCRX, valued at $3.88M.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
683 CAPITAL MANAGEMENT, LLC----43,198-100.00%-Mar 31, 2024
EXODUSPOINT CAPITAL MANAGEMENT, LP0.05%0.00%35,661-28,117-44.09%283,000Mar 31, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC0.10%0.01%63,300-25,000-28.31%502,602Mar 31, 2024
STIFEL FINANCIAL CORP0.15%0.00%101,400-19,000-15.78%805,116Mar 31, 2024
BANK OF NEW YORK MELLON CORP----16,670-100.00%-Mar 31, 2024
BOOTHBAY FUND MANAGEMENT, LLC----13,293-100.00%-Mar 31, 2024
MORGAN STANLEY0.34%0.00%223,894-10,809-4.61%1,777,719Mar 31, 2024
BANK OF AMERICA CORP /DE/0.05%-30,179-7,625-20.17%239,622,000Mar 31, 2024
BALYASNY ASSET MANAGEMENT L.P.0.06%0.00%41,942-4,044-8.79%333,019Mar 31, 2024
LAZARD ASSET MANAGEMENT LLC0.00%-2,551-1,432-35.95%19,000Mar 31, 2024
ATLAS CAPITAL ADVISORS LLC--18-878-97.99%142Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----43-100.00%-Mar 31, 2024
DEER MANAGEMENT CO. LLC1.90%1.79%1,245,504-1-0.00%9,889,302Mar 31, 2024
DC FUNDS, LP0.96%48.34%630,000--5,002,200Mar 31, 2024
LYNX1 CAPITAL MANAGEMENT LP7.96%10.75%5,224,600--41,483,324Mar 31, 2024
PROPEL BIO MANAGEMENT, LLC3.18%9.65%2,087,139--16,571,884Mar 31, 2024
ECOR1 CAPITAL, LLC7.62%1.00%5,000,000--39,700,000Mar 31, 2024
BVF INC/IL4.56%0.65%2,989,474--23,736,424Mar 31, 2024
SIMPLIFY ASSET MANAGEMENT INC.1.60%0.49%1,046,916--8,312,513Mar 31, 2024
ALPHABET INC.1.64%0.34%1,077,080--8,552,015Mar 31, 2024

As of Mar 31 2024, TScan Therapeutics's biggest institutional seller is 683 CAPITAL MANAGEMENT, LLC. The company sold -43.20K shares of TCRX, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
INVESCO LTD.0.74%0.00%488,415488,415100.00%3,878,015Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.45%0.00%297,902297,902100.00%2,365,342Mar 31, 2024
TOCQUEVILLE ASSET MANAGEMENT L.P.0.32%0.03%212,200212,200100.00%1,684,868Mar 31, 2024
MARATHON TRADING INVESTMENT MANAGEMENT LLC0.08%0.03%51,00051,000100.00%404,940Mar 31, 2024
TWO SIGMA INVESTMENTS, LP0.06%0.00%37,74737,747100.00%299,711Mar 31, 2024
HRT FINANCIAL LP0.05%0.00%34,78934,789100.00%276,000Mar 31, 2024
BREVAN HOWARD CAPITAL MANAGEMENT LP0.05%0.00%34,57834,578100.00%274,549Mar 31, 2024
POINT72 ASIA (SINGAPORE) PTE. LTD.0.03%0.04%19,73619,736100.00%156,704Mar 31, 2024
CANNON GLOBAL INVESTMENT MANAGEMENT, LLC0.03%0.37%17,50017,500100.00%138,950Mar 31, 2024
CREDIT SUISSE AG/0.03%0.00%17,36617,366100.00%137,886Mar 31, 2024
OMERS ADMINISTRATION CORP0.02%0.00%14,20014,200100.00%112,748Mar 31, 2024
JEFFERIES FINANCIAL GROUP INC.0.02%0.00%12,20012,200100.00%96,868Mar 31, 2024
CITADEL ADVISORS LLC0.02%-11,43211,432100.00%90,770Mar 31, 2024
CTC ALTERNATIVE STRATEGIES, LTD.0.02%0.05%11,00011,000100.00%87,340Mar 31, 2024
JUMP FINANCIAL, LLC0.02%0.00%10,29110,291100.00%81,711Mar 31, 2024
CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC.0.02%0.00%10,06110,061100.00%80,000Mar 31, 2024
MACQUARIE GROUP LTD0.00%-1,6181,618100.00%13Mar 31, 2024
FEDERATED HERMES, INC.0.00%-5656100.00%445Mar 31, 2024

TScan Therapeutics's largest new institutional shareholder by number of shares is INVESCO LTD., purchased 488.42K shares, valued at $3.88M, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
683 CAPITAL MANAGEMENT, LLC----43,198-100.00%-Mar 31, 2024
BANK OF NEW YORK MELLON CORP----16,670-100.00%-Mar 31, 2024
BOOTHBAY FUND MANAGEMENT, LLC----13,293-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----43-100.00%-Mar 31, 2024

TScan Therapeutics's largest sold out institutional shareholder by shares sold is 683 CAPITAL MANAGEMENT, LLC, sold -43.20K shares, valued at -, as of undefined.

TScan Therapeutics Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
BlackRock Health Sciences Trust II0.38%1,045,767-158,630-13.17%Dec 31, 2023
TEKLA HEALTHCARE INVESTORS0.12%138,057--Dec 31, 2023
TEKLA LIFE SCIENCES INVESTORS0.11%61,943--Dec 31, 2023
BlackRock Health Sciences Trust0.07%29,940--Dec 31, 2023
VANGUARD VALLEY FORGE FUNDS0.06%27,200--Dec 31, 2023
BRIDGEWAY FUNDS INC0.04%88,300--Dec 29, 2023
VANGUARD INDEX FUNDS0.00%2,261,320592,12935.47%Dec 31, 2023
BlackRock ETF Trust0.00%2,144-125-5.51%Jan 31, 2024
FIDELITY CONCORD STREET TRUST0.00%365,16048,90615.46%Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%19,120-15,244-44.36%Dec 31, 2023
AMERICAN CENTURY ETF TRUST0.00%29,26610,15653.14%Feb 29, 2024
THRIVENT SERIES FUND INC0.00%15,222--Dec 29, 2023
BLACKROCK FUNDS0.00%551,194--Feb 29, 2024
NATIONWIDE MUTUAL FUNDS0.00%8,1178,117-Jan 31, 2024
PACIFIC SELECT FUND0.00%23,807--Dec 31, 2023
EQ ADVISORS TRUST0.00%4,479--Dec 31, 2023
iSHARES TRUST0.00%57,416--Feb 29, 2024
VANGUARD SCOTTSDALE FUNDS0.00%7,166--Feb 29, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%684--Dec 31, 2023

TScan Therapeutics's largest mutual fund holder by % of total assets is "BlackRock Health Sciences Trust II", owning 1.05M shares, compromising 0.38% of its total assets.

TScan Therapeutics Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 246522.64%
31 Dec, 235370.97%
30 Sep, 23316.90%
30 Jun, 23293.57%
31 Mar, 2328-
31 Dec, 222812.00%
30 Sep, 22258.70%
30 Jun, 2223-4.17%
31 Mar, 2224-14.29%
31 Dec, 21287.69%
30 Sep, 2126-

As of 31 Mar 24, 65 institutions are holding TScan Therapeutics's shares, representing an increase of 22.64% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 2434,139,9247.33%
31 Dec, 2331,808,94111.33%
30 Sep, 2328,571,3162.16%
30 Jun, 2327,967,444189.29%
31 Mar, 239,667,5551.56%
31 Dec, 229,519,3130.12%
30 Sep, 229,508,276-1.80%
30 Jun, 229,682,0822.92%
31 Mar, 229,407,696-4.61%
31 Dec, 219,861,951-2.69%
30 Sep, 2110,134,939-

TScan Therapeutics (TCRX) has 34.14M shares outstanding as of 31 Mar 24, up 7.33% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 2452.04%4.63%
31 Dec, 2333.54%0.92%
30 Sep, 2360.52%0.45%
30 Jun, 23115.44%7.25%
31 Mar, 2339.91%2.55%
31 Dec, 2239.58%2.54%
30 Sep, 2239.50%2.44%
30 Jun, 2240.24%2.61%
31 Mar, 2239.24%1.59%
31 Dec, 2149.62%1.91%
30 Sep, 2150.99%-

As of 31 Mar 24, TScan Therapeutics is held by 52.04% institutional shareholders, representing a 4.63% growth compared to 31 Dec 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 243815.15%
31 Dec, 2333120.00%
30 Sep, 23157.14%
30 Jun, 231416.67%
31 Mar, 2312-
31 Dec, 221250.00%
30 Sep, 228-33.33%
30 Jun, 2212-
31 Mar, 2212-
31 Dec, 2112-53.85%
30 Sep, 2126-

38 institutional shareholders have increased their position in TCRX stock as of 31 Mar 24 compared to 33 in the previous quarter (a 15.15% increase).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 24980.00%
31 Dec, 235400.00%
30 Sep, 231-75.00%
30 Jun, 23433.33%
31 Mar, 233-25.00%
31 Dec, 224-33.33%
30 Sep, 226100.00%
30 Jun, 223-
31 Mar, 223-50.00%
31 Dec, 216-
30 Sep, 21--

9 institutional shareholders have reduced their position in TCRX stock as of 31 Mar 24 compared to 5 in the previous quarter (a 80.00% increase).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 246522.64%34,139,9247.33%52.04%4.63%3815.15%980.00%
31 Dec, 235370.97%31,808,94111.33%33.54%0.92%33120.00%5400.00%
30 Sep, 23316.90%28,571,3162.16%60.52%0.45%157.14%1-75.00%
30 Jun, 23293.57%27,967,444189.29%115.44%7.25%1416.67%433.33%
31 Mar, 2328-9,667,5551.56%39.91%2.55%12-3-25.00%
31 Dec, 222812.00%9,519,3130.12%39.58%2.54%1250.00%4-33.33%
30 Sep, 22258.70%9,508,276-1.80%39.50%2.44%8-33.33%6100.00%
30 Jun, 2223-4.17%9,682,0822.92%40.24%2.61%12-3-
31 Mar, 2224-14.29%9,407,696-4.61%39.24%1.59%12-3-50.00%
31 Dec, 21287.69%9,861,951-2.69%49.62%1.91%12-53.85%6-
30 Sep, 2126-10,134,939-50.99%-26---

TScan Therapeutics Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 23, 2024BAKER BROS. ADVISORS LPdirector-P-PurchaseBuy8,851,451-$885.1543,158,741
Apr 23, 2024BAKER BROS. ADVISORS LPdirector-P-PurchaseBuy825,968-$82.604,018,678
Apr 23, 2024Lynx1 Capital Management LP10 percent owner-P-PurchaseBuy5,000,000-$500.005,000,000
Dec 21, 2023BARBERICH TIMOTHY Jdirector-P-PurchaseBuy317$4.97$1.58K67,027
Dec 21, 2023BARBERICH TIMOTHY Jdirector-P-PurchaseBuy28,830$4.89$140.88K66,710
Dec 18, 2023Klencke Barbaradirector-P-PurchaseBuy5,000$5.08$25.40K30,000

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 23, 2024BAKER BROS. ADVISORS LPdirector-P-PurchaseBuy8,851,451-$885.1543,158,741
Apr 23, 2024BAKER BROS. ADVISORS LPdirector-P-PurchaseBuy825,968-$82.604,018,678
Apr 23, 2024Lynx1 Capital Management LP10 percent owner-P-PurchaseBuy5,000,000-$500.005,000,000
Dec 21, 2023BARBERICH TIMOTHY Jdirector-P-PurchaseBuy317$4.97$1.58K67,027
Dec 21, 2023BARBERICH TIMOTHY Jdirector-P-PurchaseBuy28,830$4.89$140.88K66,710
Dec 18, 2023Klencke Barbaradirector-P-PurchaseBuy5,000$5.08$25.40K30,000

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jul 24, 2023Dworak Leidenofficer Chief Accounting OfficerSell---5,692
Jul 24, 2023Dworak Leidenofficer Chief Accounting OfficerSell163,800$2.49$407.86K-
Jul 24, 2023Dworak Leidenofficer Chief Accounting OfficerSell37,500$2.90$108.75K-
Jul 24, 2023Dworak Leidenofficer Chief Accounting OfficerSell28,750$1.81$52.04K-

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
May 03, 2024Louis Chrystalofficer Chief Medical OfficerA-AwardBuy380,000$8.62$3.28M380,000
May 02, 2024Louis Chrystal-Buy----
Apr 23, 2024BAKER BROS. ADVISORS LPdirector-P-PurchaseBuy8,851,451-$885.1543,158,741
Apr 23, 2024BAKER BROS. ADVISORS LPdirector-P-PurchaseBuy825,968-$82.604,018,678
Apr 23, 2024Lynx1 Capital Management LP10 percent owner-P-PurchaseBuy5,000,000-$500.005,000,000
Feb 02, 2024Amello Jasonofficer Chief Financial OfficerA-AwardBuy750,000$5.15$3.86M750,000
Feb 02, 2024Amello Jason-Buy----
Dec 21, 2023BARBERICH TIMOTHY Jdirector-P-PurchaseBuy317$4.97$1.58K67,027
Dec 21, 2023BARBERICH TIMOTHY Jdirector-P-PurchaseBuy28,830$4.89$140.88K66,710
Dec 18, 2023Klencke Barbaradirector-P-PurchaseBuy5,000$5.08$25.40K30,000
Dec 08, 2023Woods Keithdirector-A-AwardBuy17,500$6.74$117.95K17,500
Dec 08, 2023Woods Keith-Buy----
Jul 24, 2023Dworak Leidenofficer Chief Accounting OfficerA-AwardBuy25,000$2.23$55.75K25,000
Jul 24, 2023Dworak Leidenofficer Chief Accounting OfficerSell---5,692
Jul 24, 2023Dworak Leidenofficer Chief Accounting OfficerSell163,800$2.49$407.86K-
Jul 24, 2023Dworak Leidenofficer Chief Accounting OfficerSell37,500$2.90$108.75K-
Jul 24, 2023Dworak Leidenofficer Chief Accounting OfficerSell28,750$1.81$52.04K-
Jun 15, 2023BARBERICH TIMOTHY Jdirector-A-AwardBuy35,000$2.66$93.10K35,000
Jun 15, 2023Barton Deboraofficer Chief Medical OfficerA-AwardBuy430,000$2.49$1.07M430,000
Jun 15, 2023Dorton Katinadirector-A-AwardBuy35,000$2.66$93.10K35,000

The last insider sell of TScan Therapeutics's stock was made by Dworak Leiden on Jul 24 2023, selling - shares at - per share (valued at -). The last insider buy of TCRX was made by BAKER BROS. ADVISORS LP on Apr 23 2024, buying 8,851,451 shares at - per share (worth $885.15).

TScan Therapeutics Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 20244--
Q1 20241--
Q4 20234--
Q3 20231425.00%
Q2 2023134325.00%
Q1 20234--
Q4 20222--
Q3 20227--
Q2 202218--
Q1 20226--
Q4 202111100.00%
Q3 2021182090.00%

4 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by TScan Therapeutics's insiders, as of Q2 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 20243--
Q1 2024---
Q4 20233--
Q3 2023---
Q2 20231333.33%
Q1 2023---
Q4 20222--
Q3 2022---
Q2 202211--
Q1 20221--
Q4 2021---
Q3 202111--

As of Q2 2024, Insider owners conducted 3 open market buy trades and 0 open market sell trades of TScan Therapeutics's stocks.

TScan Therapeutics Peer Ownership


TickerCompany
TERNTerns Pharmaceuticals, Inc.
ABOSAcumen Pharmaceuticals, Inc.
TFFPTFF Pharmaceuticals, Inc.
VECTVectivBio Holding AG
XFORX4 Pharmaceuticals, Inc.
ITOSiTeos Therapeutics, Inc.
INZYInozyme Pharma, Inc.
PRQRProQR Therapeutics N.V.
DAWNDay One Biopharmaceuticals, Inc.
ARWRArrowhead Pharmaceuticals, Inc.
ANNXAnnexon, Inc.
CUECue Biopharma, Inc.
APLSApellis Pharmaceuticals, Inc.
DRMADermata Therapeutics, Inc.
CGTXCognition Therapeutics, Inc.

TCRX Ownership FAQ


TScan Therapeutics is owned by institutional shareholders (52.04%), insiders (0.86%), and public (47.09%). The largest institutional shareholder of TScan Therapeutics is LYNX1 CAPITAL MANAGEMENT LP (7.96% of total shares) and the top mutual fund owner is BlackRock Health Sciences Trust II (0.38% of total shares).

TScan Therapeutics's major institutional shareholders are LYNX1 CAPITAL MANAGEMENT LP, ECOR1 CAPITAL, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., BVF INC/IL, and BAKER BROS. ADVISORS LP. The top five shareholders own together 30.33% of the company's share outstanding.

As of Mar 2024, there are 65 institutional shareholders of TScan Therapeutics.

LYNX1 CAPITAL MANAGEMENT LP owns 5.22M shares of TScan Therapeutics, representing 7.96% of the company's total shares outstanding, valued at $41.48M (as of Mar 2024).

As of Mar 2024, ECOR1 CAPITAL, LLC holds 5M shares of TScan Therapeutics (TCRX), compromising 7.62% of the company, valued at $39.7M.

ADAGE CAPITAL PARTNERS GP, L.L.C is the third largest holder of TScan Therapeutics. The company owns 3.9M of the company's shares outstanding (worth $30.97M).